Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management

Cardiovascular diseases (CVDs) remain the leading cause of death and disability worldwide, with atherosclerotic cardiovascular disease (ASCVD) accounting for the largest proportion. Vascular inflammation is a major driver of ASCVD, contributing to plaque formation, progression, and rupture and influencing myocardial repair after infarction. Conventional anti-inflammatory therapies are limited by systemic toxicity and insufficient drug accumulation at lesion sites, restricting their capacity for precise intervention. Nanomedicines can deliver therapeutics to lesion sites and release them in response to local stimuli, potentially reducing systemic toxicity and offering a promising approach to inflammation-targeted treatment of ASCVD. Existing studies have largely cataloged nanocarrier types or evaluated efficacy in isolated disease models but have not provided an integrated perspective on inflammation management across the full ASCVD continuum. This review discusses the role of nanomedicines in preventive plaque stabilization and post-interventional management, including recovery after myocardial infarction and prevention of in-stent restenosis. Preclinical studies indicate that nanomedicines can reduce atherosclerotic plaque size and infarct size and mitigate ischemia-reperfusion injury and stent intimal hyperplasia, potentially improving cardiovascular outcomes. Future work should prioritize mechanistic validation in clinically relevant models and artificial intelligence (AI)-assisted precision medicine to accelerate the safe clinical adoption of inflammation-targeted nanomedicines for CVDs.

Authors

Institutions

Publication Details

Journal
Soft Science
Published
2026-11-19
DOI
https://doi.org/10.20517/ss.2026.187
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management

Ning Gu, Mingfei Pan, Qingguo Li, Xiang Guan et al.
Soft Science
Nanoparticle-Based Drug Delivery
article

Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management

Ning Gu, Mingfei Pan, Qingguo Li, Xiang Guan, Jiangwei Chen, Feifei Wang, Yinshu Luo, Guoqiang Yang
article en

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of death and disability worldwide, with atherosclerotic cardiovascular disease (ASCVD) accounting for the largest proportion. Vascular inflammation is a major driver of ASCVD, contributing to plaque formation, progression, and rupture and influencing myocardial repair after infarction. Conventional anti-inflammatory therapies are limited by systemic toxicity and insufficient drug accumulation at lesion sites, restricting their capacity for precise intervention. Nanomedicines can deliver therapeutics to lesion sites and release them in response to local stimuli, potentially reducing systemic toxicity and offering a promising approach to inflammation-targeted treatment of ASCVD. Existing studies have largely cataloged nanocarrier types or evaluated efficacy in isolated disease models but have not provided an integrated perspective on inflammation management across the full ASCVD continuum. This review discusses the role of nanomedicines in preventive plaque stabilization and post-interventional management, including recovery after myocardial infarction and prevention of in-stent restenosis. Preclinical studies indicate that nanomedicines can reduce atherosclerotic plaque size and infarct size and mitigate ischemia-reperfusion injury and stent intimal hyperplasia, potentially improving cardiovascular outcomes. Future work should prioritize mechanistic validation in clinically relevant models and artificial intelligence (AI)-assisted precision medicine to accelerate the safe clinical adoption of inflammation-targeted nanomedicines for CVDs.

Soft ScienceVol. 6(4)
Nanjing Drum Tower Hospital (CN), Second Affiliated Hospital of Nanjing Medical University (CN), Nanjing University (CN)
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon